Compare CTS & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTS | MDXG |
|---|---|---|
| Founded | 1896 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | N/A |
| Metric | CTS | MDXG |
|---|---|---|
| Price | $44.44 | $7.01 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 207.8K | ★ 722.5K |
| Earning Date | 02-03-2026 | 10-29-2025 |
| Dividend Yield | ★ 0.36% | N/A |
| EPS Growth | ★ 3.07 | N/A |
| EPS | ★ 1.98 | 0.27 |
| Revenue | ★ $531,522,000.00 | $393,442,000.00 |
| Revenue This Year | $5.73 | $19.13 |
| Revenue Next Year | $4.00 | $2.11 |
| P/E Ratio | ★ $22.42 | $26.21 |
| Revenue Growth | 3.61 | ★ 14.77 |
| 52 Week Low | $34.02 | $5.79 |
| 52 Week High | $54.12 | $9.71 |
| Indicator | CTS | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 55.46 | 48.25 |
| Support Level | $43.62 | $6.91 |
| Resistance Level | $44.74 | $7.45 |
| Average True Range (ATR) | 1.12 | 0.25 |
| MACD | -0.09 | 0.00 |
| Stochastic Oscillator | 53.14 | 40.13 |
CTS Corp operates in the electronics industry. The company is a manufacturer of Sensors, Electronic components, and Actuators. It designs, manufactures, and sells a broad line of sensors, electronic components, and actuators mainly to original equipment manufacturers (OEM) for the aerospace and defense, industrial, information technology, medical, telecommunications, and transportation markets. Geographically, it derives a majority of its revenue from the United States and also has a presence in China; Singapore; the Czech Republic; Taiwan, Denmark, and other countries.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.